• Cancer

    Drug Induces Morphologic, Molecular and Clinical Remissions in Myelofibrosis

Imetelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis. Hematologist and lead author of the Mayo Clinic study, Ayalew Tefferi, M.D., says, “These are early results but they are promising. Some patients in our clinical trial taking imetelstat obtained dramatic responses and there have been some complete responses which is almost unheard of for drug therapy in this disease.”
These results are being presented at the 2013 American Society of Hematology Annual Meeting in New Orleans.

Click here for news release.

Journalists: Sound bites with Dr. Tefferi are available in the downloads.